At Day 28 after MI with treatment, the numbers of CD206+ cells in the infarct and border myocardium remained greater in the IL-4c-treated hearts compared to those of the PBS control (Supplementary Fig. S2). This evidence concerns the gene MRC1 and myocardial infarction.